PATIENT PERCEPTION OF TREATMENT WITH LONG-TERM DUPILUMAB MONOTHERAPY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

被引：0
|
作者：
Simpson, E.
Lacour, J.
Beck, L.
Zhang, H.
Aamodt, K.
Rossi, A.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2021年 / 127卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P196
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 50 条
  • [21] Dupilumab provides long-term efficacy over 2-5 years in adults with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Bissonnette, R.
    Wollenberg, A.
    Simpson, E. L.
    Thaci, D.
    Praestgaard, A.
    Aamodt, K.
    Rossi, A. B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E139 - E140
  • [22] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    Frampton, James E.
    Blair, Hannah A.
    [J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
  • [23] Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab
    Cioppa, Vittoria
    Lazzeri, Laura
    Carraro, Andrea
    De Piano, Ernesto
    Falcinelli, Francesca
    Galluzzo, Marco
    Pallotta, Sabatino
    De Pita, Ornella
    Russo, Filomena
    [J]. DERMATITIS, 2024, 35
  • [24] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    [J]. American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
  • [25] Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
    Marjolein S. de Bruin-Weller
    Esther Serra-Baldrich
    Sebastien Barbarot
    Susanne Grond
    Christopher Schuster
    Helmut Petto
    Jean-Philippe Capron
    Afaf Raibouaa
    Thomas Werfel
    [J]. Dermatology and Therapy, 2022, 12 : 1481 - 1491
  • [26] Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
    de Bruin-Weller, Marjolein S.
    Serra-Baldrich, Esther
    Barbarot, Sebastien
    Grond, Susanne
    Schuster, Christopher
    Petto, Helmut
    Capron, Jean-Philippe
    Raibouaa, Afaf
    Werfel, Thomas
    [J]. DERMATOLOGY AND THERAPY, 2022, 12 (06) : 1481 - 1491
  • [27] Impact of dupilumab treatment on seasonal disease severity in adults with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Simpson, Eric L.
    Ramien, Michele
    Tang, Mark
    Joyce, Joel C.
    Praestgaard, Amy
    Rossi, Ana B.
    Clearfield, Drew
    Zhang, Annie
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [28] A study into the drug dupilumab in Japanese adults with moderate-to-severe atopic dermatitis
    不详
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (01) : E4 - E4
  • [29] Long-term Dupilumab treatment up to 100 weeks reduces serum biomarkers in patients with moderate-to-severe atopic dermatitis
    Beck, Lisa A.
    Thaci, Diamant
    Bissonette, Robert
    Deleuran, Mette
    Harel, Sivan
    McDonald, Robert
    Shumel, Brad
    Rossi, Ana B.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 168 - 168
  • [30] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
12345